Albumin News and Research

RSS

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which were published today by the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.

3 Jul 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

21 May 2013

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

20 May 2013

Researchers unravel a mystery about how pancreatic tumor cells feed themselves

In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options.

14 May 2013

Organic pollutants increase nephropathy risk in diabetes

Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.

29 Apr 2013

Kidney disease screening needs rethink in hypertension

The standard approach to detecting chronic kidney disease fails to spot the condition in about a quarter of patients with hypertension, a study suggests.

29 Apr 2013

Nephropathy risk lowered by glucose, BP control in Type 1 diabetes

Individuals with Type 1 diabetes should keep good control of their blood sugar levels and blood pressure to reduce their risk for developing nephropathy, say researchers.

29 Apr 2013

Study confirms crizotinib drug reduces testosterone levels

A previous study by the University of Colorado Cancer Center reported the common side effect of low testosterone in men treated with the recently approved lung cancer agent, crizotinib.

17 Apr 2013

New study shows exposure to tobacco smoke could negatively impact adolescent kidney function

Exposure to tobacco smoke could negatively impact adolescent kidney function; this is according to a new study led by a team of researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Children's Center.

9 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Resuscitation with colloids not recommended

Resuscitation with colloids does not appear to decrease the risk for death, and may even increase mortality, a comprehensive study of trial data reveals.

8 Mar 2013

Carbamylation contributes to heart disease risk among patients with CKD undergoing dialysis

Kidney failure affects 25 million individuals in the U.S. and many more throughout the world. Loss of kidney function means the majority of these patients must undergo dialysis treatments to remove excess fluids and waste products. Although dialysis therapy coupled with medication has improved the life expectancy for people with kidney failure, for unknown reasons, patients' risk of sudden heart failure and death remains 10 to 20 times greater than average.

7 Mar 2013

Hydroxyethyl starch associated with increased risk of death and acute kidney injury

In an analysis of studies that examined critically ill patients requiring an increase in blood fluid volume, intravenous use of the fluid hydroxyethyl starch was not associated with decreased mortality, according to an article appearing in the February 20 issue of JAMA.

21 Feb 2013

Early PBC prognosis advocated

Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.

18 Feb 2013

Tumor necrosis factor receptor 2 involved in renal decline in diabetes

Researchers have found that circulating levels of tumor necrosis factor receptor 2 are independently associated with the development of chronic kidney disease in nonobese Japanese patients with Type 2 diabetes.

8 Feb 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Albumin may prove a predictor for pneumonia outcomes

Researchers say that assessing serum albumin levels within 24 hours of admission could be a good prognostic marker of community-acquired pneumonia.

21 Jan 2013

Albumin News and Research

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

Researchers unravel a mystery about how pancreatic tumor cells feed themselves

Organic pollutants increase nephropathy risk in diabetes

Kidney disease screening needs rethink in hypertension

Nephropathy risk lowered by glucose, BP control in Type 1 diabetes

Study confirms crizotinib drug reduces testosterone levels

New study shows exposure to tobacco smoke could negatively impact adolescent kidney function

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Resuscitation with colloids not recommended

Carbamylation contributes to heart disease risk among patients with CKD undergoing dialysis

Hydroxyethyl starch associated with increased risk of death and acute kidney injury

Early PBC prognosis advocated

Tumor necrosis factor receptor 2 involved in renal decline in diabetes

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Albumin may prove a predictor for pneumonia outcomes

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News